The PDUFA action date for an FDA decision for linvoseltamab to treat adult patients with relapsed/refractory multiple myeloma ...
Acceptance follows resolution of third-party fill/finish manufacturing issues FDA decision expected by July 10, 2025 TARRYTOWN, N.Y., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc.
20h
Acceptance follows resolution of third-party fill/finish manufacturing issuesFDA decision expected by July 10, 2025 TARRYTOWN, N.Y., Feb. 11, ...
Regeneron, which is seeking FDA approval of linvoseltamab for adults with relapsed/refractory multiple myeloma that has progressed after at least three prior therapies, said the agency set a new ...
CHICAGO, IL / ACCESS Newswire / February 10, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in ...
Dr. Reddy’s (NYSE:RDY) on Thursday announced a licensing agreement with China-based Shanghai Henlius Biotech (OTCPK:SGBCF) to jointly develop and market a biosimilar version of Darzalex, a multiple ...
So, we now have multiple new classes of drugs, multiple agents that are FDA-approved for the treatment of multiple myeloma, more than 15, 16 different drugs that have become available in that period.
In this video, Sham Mailankody, MBBS discusses the current state of the pipeline for developing multiple myeloma treatments.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback